Work

Long-Term Impact of Lumacaftor/Ivacaftor Treatment on Cystic Fibrosis Disease Progression in Children 2–5 Years of Age Homozygous for F508del-CFTR : A Phase 2, Open-Label Clinical Trial

Year: 2024

Type: article

Source: Annals of the American Thoracic Society

DOI: 10.1513/annalsats.202402-201oc

Authors: Mirjam Stahl, Jobst Roehmel, Monika Eichinger, Felix Doellinger, Lutz Naehrlich, Matthias V. Kopp, Anna-Maria Dittrich, Olaf Sommerburg, Partha Ray, Anita Maniktala, Tu Xu, Sarah Conner, Aniket Joshi, Molly Mascia, Mark O. Wielpütz, Marcus A. Mall

Institutions: Humboldt-Universität zu Berlin, German Center for Lung Research, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Charité - Universitätsmedizin Berlin, Heidelberg University, University Hospital Heidelberg, Freie Universität Berlin, Justus-Liebig-Universität Gießen, Universities of Giessen and Marburg Lung Center, University of Bern, University Hospital of Bern, Medizinische Hochschule Hannover, Vertex Pharmaceuticals (United States)

Language: English

Topic: Cystic Fibrosis Research Advances

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4401740123

FWCI: 3.558

Cites: 43

Cited by: 14

Related to: 10